1. The Atezolizumab group demonstrated significantly greater progression-free and overall survival among patients with metastatic, persistent, or recurrent cervical cancer. 2. Grade 3 or worse adverse events were comparable in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: A previous large-scale trial has shown improved overall survival among patients with cervical cancer treated with bevacizumab and
1. The Atezolizumab group demonstrated significantly greater progression-free and overall survival among patients with metastatic, persistent, or recurrent cervical cancer. 2. Grade 3 or worse adverse events were comparable in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: A previous large-scale trial has shown improved overall survival among patients with cervical cancer treated with
The use of FOLFOXIRI plus bevacizumab increased in patients with metastatic colorectal cancer from 2013 to 2022, especially in patients 50 years of age or younger.